![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page0007.jpg)
allied
academies
Page 27
Virology Research Journal
Volume 1 Issue 4
Notes:
Vaccines World 2017
November 09-10, 2017 Vienna, Austria
21
st
World Congress and Exhibition on
VACCINES, VACCINATION & IMMUNIZATION
Geert Vanden Bossche, Virol Res J 2017, 1:4
Translational Vaccinology: A myth?
Biography
Geert Vanden Bossche obtained his DVM at the Veterinary Faculty of Ghent and his PhD in Virology at the University of Hohenheim, Stuttgart. Following his Postdoctoral
training in Virology, Immunology and Molecular Biology at the Free University of Berlin and the University of Hohenheim (Germany), he was given the Venia Legendi and
subsequently held adjunct faculty appointments at the University of Hohenheim (Germany), the University of Leuven (Belgium) and the European Faculty for Environmental
Sanitation at the University of Ghent (Belgium). He then transitioned to the Vaccine Industry to serve various senior roles in both early and late vaccine development
(GSK, Novartis, Solvay). In 2008, he joined the Bill & Melinda Gates Foundation in Seattle to serve as Senior Program Officer in Vaccine Discovery for Global Health.
Furthermore, he also founded UNIVAC LLC, a start-up vaccine company, and coordinated the Ebola Vaccine Program on behalf of GAVI. He is now the Head of Vaccine
Development Office at the German Center for Infection Research (DZIF) in Germany. He is board certified in Virology and Microbiology, the author of over 30 publications,
and inventor on a patent application for universal vaccines. He has presented vaccine- and adjuvant-related topics at multiple international congresses.
geert.vandenbossche@live.beGeert Vanden Bossche
German Center for Infection Research (DZIF), Germany